NCT05886920
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05886920
Title A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors D3 Bio (Wuxi) Co., Ltd
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | AUS

Facility Status City State Zip Country Details
D3 Bio Investigative Site RECRUITING Detroit Michigan 48202 United States Details
D3 Bio Investigative Site COMPLETED New York New York 10029 United States Details
D3 Bio Investigative Site RECRUITING Nashville Tennessee 37203 United States Details
D3 Bio Investigative Site COMPLETED Blacktown New South Wales 2148 Australia Details
D3 Bio Investigative Site RECRUITING Macquarie Park New South Wales 2109 Australia Details
D3 Bio Investigative Site COMPLETED Bedford Park South Australia 5042 Australia Details
D3 Bio Investigative Site COMPLETED Nedlands Western Australia 6009 Australia Details
D3 Bio Investigative Site RECRUITING Beijing Beijing Municipality 100142 China Details
D3 Bio Investigative Site RECRUITING Guangzhou Guangdong 510080 China Details
D3 Bio Investigative Site COMPLETED Harbin Heilong Jiang 150081 China Details
D3 Bio Investigative Site RECRUITING Wuhan Hubei 430079 China Details
D3 Bio Investigative Site ACTIVE_NOT_RECRUITING Shanghai Shanghai Municipality 201801 China Details
D3 Bio Investigative Site RECRUITING Hangzhou Zhejiang 310009 China Details
D3 Bio Investigative Site RECRUITING Seoul 03722 South Korea Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field